Study Links Higher Asprosin to Less Weight Gain After Menopause

Why It Matters

The study identifies asprosin as a potential biomarker and therapeutic target for preventing menopause‑related weight gain, a key driver of cardiometabolic risk in aging women.

Key Takeaways

• Higher asprosin linked to reduced weight gain post‑menopause
• Study used >4,000 women from Women’s Health Initiative
• Non‑obese, non‑diabetic women benefited most
• High asprosin lowered major weight gain risk by 43%
• Effect diminished with insulin resistance or diabetes

Pulse Analysis

Menopause often triggers a shift in body composition, with many women experiencing increased fat mass and heightened cardiometabolic risk. While lifestyle factors play a role, hormonal changes are increasingly recognized as central drivers of weight trajectories. Asprosin, a fasting‑induced hormone secreted by adipose tissue, has been studied for its appetite‑stimulating and glucose‑raising effects, but its long‑term influence on weight stability in postmenopausal populations remained unclear until now.

The UC Irvine team leveraged the extensive Women’s Health Initiative cohort, measuring baseline asprosin levels and tracking weight, fat, and lean mass over three years. Their analysis revealed a clear gradient: women in the top asprosin quartile experienced markedly less weight gain and were substantially more likely to lose weight compared with those in the lowest quartile. Importantly, the benefit was confined to participants without pre‑existing obesity or diabetes, indicating that intact metabolic health may be required for asprosin’s protective signaling. The study also highlighted a trade‑off, as some weight loss reflected reductions in lean muscle, underscoring the need for nuanced interventions.

These findings open new avenues for precision obesity prevention in aging women. If future trials confirm that modulating asprosin can safely enhance weight stability without compromising muscle mass, pharmaceutical firms may pursue asprosin agonists or lifestyle programs that boost its endogenous production. Moreover, clinicians could incorporate asprosin screening into risk‑assessment models to identify women most likely to benefit from targeted dietary or exercise regimens. Continued research will be critical to clarify the hormone’s role in type 2 diabetes onset and to translate these epidemiologic insights into actionable therapies.